Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20200292
    Release date: 22 January 2021

    Promoter – Financial Intermediary

    MINORYX THERAPEUTICS SL

    Location

    Description

    Financing novel therapies for orphan genetic diseases of the central nervous system (CNS) with high unmet medical need.

    Objectives

    The proposed transaction will support research and development (R&D) investments that are required in order to further advance the Promoter's product pipeline and bring the products to market.

    Sector(s)

    • Health - Human health and social work activities

    Proposed EIB finance (Approximate amount)

    EUR 25 million

    Total cost (Approximate amount)

    EUR 53 million

    Environmental aspects

    The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

    Procurement

    The Promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

    Status

    Signed - 16/10/2020

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    Spain Health